Biodegradable Polymers

JenKem Technology offers high quality biodegradable polymers and co-polymers. The interest in biodegradable polymers for the medical and pharmaceutical field stems from the need for extended release drug delivery systems; and for degradable medical devices that do not require human intervention for removal from the body. JenKem® PEGs are ideal candidates as a polymeric backbone, as they have already been successfully applied for wound sealing and healing, controlled drug delivery, and tissue engineering

JenKem PEG Products

Synthetic JenKem PEG co-polymers and PEG derivatives offer several advantages over natural biodegradable polymers:

  • Highly hydrophilic
  • Facile introduction of functional groups for drug attachment
  • Production of JenKem PEGs back-integrated to ethylene oxide raw material
  • Predictable lot-to-lot consistency and raw material sourcing
  • No immunogenicity normally associated with natural polymers 
  • PEG co-polymers have applications in micelles, micro/nanoparticles, hydrogel formulations for drug encapsulation, controlled or sustained release drug delivery
  • PEG NHS Products with Cleavable Linker
    PEG PRODUCT SUBSTITUTION REACTIVITY DETAILS
    M-PEG-SS ≥ 95% Methoxy PEG Succinimidyl Succinate is a degradable PEG linker reacting with the amino group of lysine(s) on proteins or other biologics, such as the active ingredients of Adagen®, Pegademase, PEG aspargase, PEG-L-asparaginase, or PEG-adenosine deaminase, and related biosimilars, at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.[1,2]
    M-PEG-SG ≥ 95% Methoxy PEG Succinimidyl Glutarate is a degradable PEG linker that reacts with the amino group of lysine(s) on proteins or other biologics at pH 7-8, while the ester linkage is cleaved under regular ester cleaving reaction conditions.

    For more information on degradable/ cleavable JenKem® PEG linkers with various branching and molecular weights for controlled release drug delivery, please click here.

    Please see below a selection of JenKem® biodegradable PEG copolymers for time release applications, with oligopeptides polyglutamic acid and PLL (PolyL-lysine) [4-15];  PLA (polylactic acid) [1-2]; and PCL (polycaprolactone). Different copolymers, such as PGA (PolyGlycolide), or PLGA (Poly(lactic-co-glycolic acid) PEGs [3], may be available by custom synthesis – please contact us for details.

    Poly(Glutamic acid) PEGs
    PEG PRODUCT PURITY ITEM DESCRIPTION
    M-PEG-GLU2 ≥95% M-PEG-GLU2 Methoxy PEG Di-Glutamic Acid (mPEG-PGA)
    M-PEG-GLU3 ≥90% M-PEG-GLU3 Methoxy PEG Tri-Glutamic Acid (mPEG-PGA)
    Poly(L-lysine) Linear PEGs (Methoxy PEG PLL)
    PEG PRODUCT Main peak fraction (wt%) ITEM DESCRIPTION
    PLL20K-G35-PEG2K ≥90% PLL20K-G35-PEG2K, PEG-Poly(L-lysine), Poly(L-lysine), Graft Ratio 3.5, PLL MW 20000, PEG MW 2000
    PolyLactide Multiarm PEGs (4arm PEG PLA)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    4ARM-PEG2500-b-PLA2500 ≥95% 4ARM-PEG2500-b-PLA2500, 4arm Polyethylene Glycol Polylactide Block Copolymer, PEG MW 2500, PLA MW 2500
    PolyLactide Linear PEGs (PLA PEGs)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    MPEG5000-b-PLA2500 ≥90% MPEG5000-b-PLA2500, Methoxy Polyethylene Glycol Polylactide Block Copolymer, PEG MW 5000, PLA MW 2500
    MPEG5000-b-PLA5000 ≥90% MPEG5000-b-PLA5000, Methoxy Polyethylene Glycol Polylactide Block Copolymer, PEG MW 5000, PLA MW 5000
    PolyLactide Linear PEG Derivatives (PLA PEG Derivatives)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    MAL-PEG5000-b-PLA20K ≥90% MAL-PEG5000-b-PLA20K, Maleimide Polyethylene Glycol Polylactide block copolymer, PEG MW 5000, PLA MW 20000, Substitution (Maleimide) ≥ 70%
    MAL-PEG2000-b-PLA2000 ≥90% MAL-PEG2000-b-PLA2000, Maleimide Polyethylene Glycol Polylactide block copolymer, PEG MW 2000, PLA MW 2000, Substitution (Maleimide) ≥ 70%
    PolyCaprolactone Multiarm PEGs (4arm PCL PEGs)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    4ARM-PEG2500-b-PCL2500 ≥95% 4ARM-PEG2500-b-PCL2500, 4arm Polyethylene Glycol Polycaprolactone Block Copolymer, PEG MW 2500, PCL MW 2500
    PolyCaprolactone Linear PEGs (Methoxy PEG PCL)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    MPEG2000-b-PCL2000 ≥90% MPEG2000-b-PCL2000, Methoxy PEG Polycaprolactone Block Copolymer, PEG MW 2000, PCL MW 2000
    Poly(Lactide-co-glycolide) Linear PEGs (Methoxy PEG PLGA)
    PEG PRODUCT PURITY ITEM DESCRIPTION
    COOH-PEG5000-b-PLGA5000 >90% COOH-PEG5000-b-PLGA5000, Carboxyl Polyethelyene glycol poly (Lactide-co-glycolide) diblock copolymer, PEG MW 5000, PLGA MW 5000

    Order online
    References:

    1. Prezel, E., et al., TIRF assays for real-time observation of microtubules and actin coassembly: Deciphering tau effects on microtubule/actin interplay, Methods in Cell Biology, 2017.

    2. Jin, Q., et al., Edaravone-Encapsulated Agonistic Micelles Rescue Ischemic Brain Tissue by Tuning Blood-Brain Barrier Permeability, Theranostics, 2017, 7(4):884.

    3. Hao, Y., et al., The evaluation of cellular uptake efficiency and tumor-target ability of MPEG-PDLLA micelles: Effect of particle size. RSC Advances. 2016, 17.

    4. Liang, H., et al., Size-Shifting Micelle Nanoclusters Based on a Cross-Linked and pH-Sensitive Framework for Enhanced Tumor Targeting and Deep Penetration Features. ACS applied materials & interfaces. 2016, 8(16):10136-46.

    5. Li, Q., et al., Development of reactive oxygen species (ROS)-responsive nanoplatform for targeted oral cancer therapy. Journal of Materials Chemistry B. 2016.

    6. Schaedel, L., et al., Microtubules self-repair in response to mechanical stress, Nature Mater., 2015, 14(11):1156-63.

    7. Bhajun, R., et al., A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator, Scientific Reports, 2015, 5, Article number: 8336.

    8. Portran, D., et al., Micropatterning Microtubules, Methods in Cell Biology 2014, Matthieu P, Manuel T (Editors) Academic Press, USA, 39-51.

    9. Boujemaa-Paterski, R., et al., Directed actin assembly and motility, Methods Enzymol 2014, 540: 283-300.

    10. Vignaud, T., et al., Polyacrylamide hydrogel micropatterning, Methods Cell Biol 2014, 120: 93-116.

    11. Reymann, A.-C., et al, Nucleation geometry governs ordered actin networks structures, Nature Materials 2010, 9, 827-832.

    12. Kiss, A., et al., Nuclear Motility in Glioma Cells Reveals a Cell-Line Dependent Role of Various Cytoskeletal Components, PLoS ONE 2014, 9(4): e93431.

    13. Portran, D., et al., Quantification of MAP and molecular motor activities on geometrically controlled microtubule networks, Cytoskeleton, 2013, 70: 12–23. doi: 10.1002/cm.21081.

    14. Schiller, H.B., et al., β1-and αv-class integrins cooperate to regulate myosin II during rigidity sensing of fibronectin-based microenvironments, Nature cell biology 2013, 15.6 : 625-636.

    15. Galland, R., et al., Fabrication of three-dimensional electrical connections by means of directed actin self-organization, Nature materials 2013, 12.5 : 416-421.

    16. Portran, D., et al., MAP65/Ase1 promote microtubule flexibility, Molecular biology of the cell, 2013; 24(12):1964-73.

    17. Pitaval, A., et al., Cell shape and contractility regulate ciliogenesis in cell cycle–arrested cells, JCB, 2010, 191 (2):303-312.

    Founded in 2004 by recognized experts in PEG synthesis and PEGylation, JenKem Technology specializes exclusively in the development and manufacturing of high quality polyethylene glycol (PEG) products and derivatives, and related custom synthesis and PEGylation services. JenKem Technology is ISO 9001 and ISO 13485 certified, and adheres to ICH Q7A guidelines for GMP manufacture. The production of JenKem® PEGs is back-integrated to on-site manufacturing from ethylene oxide, enabling facile traceability for GMP regulated customers. JenKem Technology caters to the PEGylation needs of the pharmaceutical, biotechnology, medical device and diagnostics, and emerging chemical specialty markets, from laboratory scale through large commercial scale.

    Continue Reading